Biblio Discovery — Demo Discovery Service

85 results for "Shaji Kumar"

Showing 1–20 · 0.22 seconds · RSS

  1. Journal Article

    One disease, many faces

    Shaji Kumar

    Haematologica, Vol. 108 No. 5 · 2022 · English · DOAJ Scopus

  2. Journal Article

    Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma

    Utkarsh Painuly; Shaji Kumar

    Clinical Medicine Insights: Oncology, Vol. 7 · 2013 · English · DOAJ Scopus

    Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that…

    Also available at: DOAJ

  3. Journal Article

    Extramedullary disease in multiple myeloma

    Radhika Bansal; Sagar Rakshit; Shaji Kumar

    Blood Cancer Journal, Vol. 11 No. 9 · 2021 · English · DOAJ Scopus

    Abstract When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows contiguous from osseous lesions that break through the cortical bone, it is referred to as extramedullary multiple myeloma (EMD). EMD remains challenging from a therapeutic and biological perspective. The…

  4. Journal Article

    Cutaneous manifestations of monoclonal gammopathy

    Jean-Sebastien Claveau; David A. Wetter; Shaji Kumar

    Blood Cancer Journal, Vol. 12 No. 4 · 2022 · English · DOAJ Scopus

    Abstract Monoclonal gammopathy associated with dermatological manifestations are a well-recognized complication. These skin disorders can be associated with infiltration and proliferation of a malignant plasma cells or by a deposition of the monoclonal immunoglobulin in a nonmalignant monoclonal…

  5. Journal Article

    Monoclonal gammopathy of clinical significance: a multisystem review

    Manraj Singh Sra; S. Vincent Rajkumar; Shaji Kumar

    Blood Cancer Journal, Vol. 16 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Monoclonal gammopathy of clinical significance (MGCS) is a general term that encompasses a spectrum of non-malignant clinical disorders that are directly caused by monoclonal immunoglobulins (monoclonal proteins) produced by clonal plasma cell proliferative disorders. It is best considered…

  6. Journal Article

    Practice, prescription habits, experience and perception of Indian homeopathic practitioners in treatment of diabetes mellitus: An online observational study

    Roja Varanasi; Amit Srivastava; Shaji Kumar RT et al.

    Journal of Ayurveda and Integrative Medicine, Vol. 14 No. 5 · 2023 · English · DOAJ Scopus

    Background: Studies have shown homoeopathy to effectively control blood sugar levels and improve quality of life (QOL), though a standard treatment protocol is required. Objective: This study intended to assess the homoeopathic practice, prescription habits, experience, and perception of Indian…

  7. Journal Article

    Design improvement of screw down stop valve assembly through K Means clustering algorithm

    Sidhant Singh; Abhinav Shaji Kumar; Akilan S. et al.

    Cogent Engineering, Vol. 12 No. 1 · 2025 · English · DOAJ Scopus

    Design improvement is becoming vital for enhancing product performance, reducing costs and meeting customer needs and market demands. Recent advancements utilize clustering algorithms for supporting informed decision making by grouping similar objects based on common characteristics. Among other…

  8. Journal Article

    Smoldering multiple myeloma current treatment algorithms

    S. Vincent Rajkumar; Shaji Kumar; Sagar Lonial et al.

    Blood Cancer Journal, Vol. 12 No. 9 · 2022 · English · DOAJ Scopus

    Abstract Smoldering multiple myeloma (SMM) is an asymptomatic condition that occupies a space between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) along the spectrum of clonal plasma cell proliferative disorders. It is not a biologic intermediate stage between…

  9. Journal Article

    Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression

    Alissa Visram; Surendra Dasari; Emilie Anderson et al.

    Blood Cancer Journal, Vol. 11 No. 3 · 2021 · English · DOAJ Scopus

    Abstract Immunotherapy has shown efficacy in relapsed multiple myeloma (MM). However, these therapies may depend on a functional tumor immune microenvironment (iTME) for their efficacy. Characterizing the evolution of the iTME over the disease course is necessary to optimize the timing of…

  10. Journal Article Full text

    Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway

    Vijay Ramakrishnan; Teresa Kimlinger; Jessica Haug et al.

    PLoS ONE, Vol. 7 No. 11 · 2012 · English · PLOS Scopus

    The PI3K/Akt/mTOR signal transduction pathway plays a central role in multiple myeloma (MM) disease progression and development of therapeutic resistance. mTORC1 inhibitors have shown limited efficacy in the clinic, largely attributed to the reactivation of Akt due to rapamycin induced mTORC2…

  11. Journal Article

    Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR

    Qiumei Yao; Yinlei Bai; Shaji Kumar et al.

    Frontiers in Oncology, Vol. 10 · 2021 · English · DOAJ Scopus

    Here we compared clonotype identification by allele-specific oligonucleotide real-time quantitative-PCR (ASO RQ-PCR) and next-generation sequencing (NGS) in 80 multiple myeloma patients. ASO RQ-PCR was applicable in 49/55 (89%) and NGS in 62/78 (80%). Clonotypes identified by both methods were…

  12. Journal Article

    Case series: MRD negativity assessment using C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma

    Cheong Ngai; Shaji Kumar; Garrett Chi-lai Ho et al.

    Therapeutic Advances in Hematology, Vol. 12 · 2021 · English · DOAJ Scopus

    Complete response (CR) is an important favorable factor for survival in multiple myeloma (MM). However, CR patients continue to relapse, especially in the presence of minimal residual disease (MRD). Bone marrow (BM) MRD is predictive of progression-free survival (PFS) in MM. However, myeloma…

  13. Journal Article

    Front‐line treatment patterns in multiple myeloma: An analysis of U.S.‐based electronic health records from 2011 to 2019

    Shaji Kumar; Mellissa Williamson; Uzor Ogbu et al.

    Cancer Medicine, Vol. 10 No. 17 · 2021 · English · DOAJ Scopus

    Abstract Multiple myeloma (MM) treatment options have evolved rapidly, but how new agents are incorporated into treatment decisions in current practice is not well understood. This study examined prescribing trends of physicians treating newly diagnosed MM and treatment outcomes in the United…

  14. Journal Article Full text

    RWD-derived response in multiple myeloma

    Tao Xu; James Roose; Mellissa Williamson et al.

    PLOS ONE, Vol. 18 No. 5 · 2023 · English · PLOS Scopus

    Real-world data (RWD) are important for understanding the treatment course and response patterns of patients with multiple myeloma. This exploratory pilot study establishes a way to reliably assess response from incomplete laboratory measurements captured in RWD. A rule-based algorithm, adapted…

  15. Journal Article

    Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance

    Alexander J. Ryu; Shaji Kumar; Angela Dispenzieri et al.

    Blood Cancer Journal, Vol. 13 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Monoclonal gammopathy of undetermined significance (MGUS) is a benign hematological condition with the potential to progress to malignant conditions including multiple myeloma and Waldenstrom macroglobulinemia. Medications that modify progression risk have yet to be identified. To…